Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease

The case of amyloid precursor protein

Monica Di Luca, Francesca Colciaghi, Lucia Pastorino, Barbara Borroni, Alessandro Padovani, Flaminio Cattabeni

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Alzheimer disease is a progressive neurodegenerative disease, characterised by a progressive cognitive and memory decline. From a neuropathological point of view, Alzheimer disease is defined by the presence of characteristic lesions, i.e. mature senile plaques, neurofibrillary tangles (NFTs) and amyloid angiopathy. In particular, accumulation of the amyloid β-peptide in the brain parenchyma and vasculature is an invariant event in the pathogenesis of both sporadic and familial Alzheimer cases. Amyloid β-peptide originates from a larger precursor, the amyloid precursor protein (APP) ubiquitously expressed. Among the different peripheral cells expressing APP forms, platelets are particularly interesting since they show concentrations of its isoforms equivalent to those found in brain. Moreover, a number of laboratories independently described alterations in APP metabolism/concentration in platelets of Alzheimer patients when compared to control subjects matched for demographic characteristics. These observations defined the frame of our work aimed to investigate if a correlation between levels of platelet APP forms and Alzheimer disease could be detected. We have reported that patients affected by Alzheimer disease show a differential level of platelet APP forms. This observation has several implications: APP processing abnormalities, believed to be a very early change in Alzheimer disease in neuronal compartment, do occur in extraneuronal tissues, such as platelets, thus, suggesting that Alzheimer disease is a systemic disorder; further, our data strongly indicate that a differential level of platelet APP isoforms can be considered a potential peripheral marker of Alzheimer disease allowing for discrimination between Alzheimer and other types of dementia. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)277-283
Number of pages7
JournalEuropean Journal of Pharmacology
Volume405
Issue number1-3
DOIs
Publication statusPublished - Sep 29 2000

Fingerprint

Amyloid beta-Protein Precursor
Alzheimer Disease
Blood Platelets
Amyloid
Protein Isoforms
Peptides
Neurofibrillary Tangles
Amyloid Plaques
Brain
Neurodegenerative Diseases
Demography

Keywords

  • Alzheimer disease
  • Amyloid precursor protein (APP)
  • Diagnosis
  • Platelet

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease : The case of amyloid precursor protein. / Di Luca, Monica; Colciaghi, Francesca; Pastorino, Lucia; Borroni, Barbara; Padovani, Alessandro; Cattabeni, Flaminio.

In: European Journal of Pharmacology, Vol. 405, No. 1-3, 29.09.2000, p. 277-283.

Research output: Contribution to journalArticle

Di Luca, Monica ; Colciaghi, Francesca ; Pastorino, Lucia ; Borroni, Barbara ; Padovani, Alessandro ; Cattabeni, Flaminio. / Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease : The case of amyloid precursor protein. In: European Journal of Pharmacology. 2000 ; Vol. 405, No. 1-3. pp. 277-283.
@article{d6de9e3667214a539434cfb422350703,
title = "Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease: The case of amyloid precursor protein",
abstract = "Alzheimer disease is a progressive neurodegenerative disease, characterised by a progressive cognitive and memory decline. From a neuropathological point of view, Alzheimer disease is defined by the presence of characteristic lesions, i.e. mature senile plaques, neurofibrillary tangles (NFTs) and amyloid angiopathy. In particular, accumulation of the amyloid β-peptide in the brain parenchyma and vasculature is an invariant event in the pathogenesis of both sporadic and familial Alzheimer cases. Amyloid β-peptide originates from a larger precursor, the amyloid precursor protein (APP) ubiquitously expressed. Among the different peripheral cells expressing APP forms, platelets are particularly interesting since they show concentrations of its isoforms equivalent to those found in brain. Moreover, a number of laboratories independently described alterations in APP metabolism/concentration in platelets of Alzheimer patients when compared to control subjects matched for demographic characteristics. These observations defined the frame of our work aimed to investigate if a correlation between levels of platelet APP forms and Alzheimer disease could be detected. We have reported that patients affected by Alzheimer disease show a differential level of platelet APP forms. This observation has several implications: APP processing abnormalities, believed to be a very early change in Alzheimer disease in neuronal compartment, do occur in extraneuronal tissues, such as platelets, thus, suggesting that Alzheimer disease is a systemic disorder; further, our data strongly indicate that a differential level of platelet APP isoforms can be considered a potential peripheral marker of Alzheimer disease allowing for discrimination between Alzheimer and other types of dementia. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Alzheimer disease, Amyloid precursor protein (APP), Diagnosis, Platelet",
author = "{Di Luca}, Monica and Francesca Colciaghi and Lucia Pastorino and Barbara Borroni and Alessandro Padovani and Flaminio Cattabeni",
year = "2000",
month = "9",
day = "29",
doi = "10.1016/S0014-2999(00)00559-8",
language = "English",
volume = "405",
pages = "277--283",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease

T2 - The case of amyloid precursor protein

AU - Di Luca, Monica

AU - Colciaghi, Francesca

AU - Pastorino, Lucia

AU - Borroni, Barbara

AU - Padovani, Alessandro

AU - Cattabeni, Flaminio

PY - 2000/9/29

Y1 - 2000/9/29

N2 - Alzheimer disease is a progressive neurodegenerative disease, characterised by a progressive cognitive and memory decline. From a neuropathological point of view, Alzheimer disease is defined by the presence of characteristic lesions, i.e. mature senile plaques, neurofibrillary tangles (NFTs) and amyloid angiopathy. In particular, accumulation of the amyloid β-peptide in the brain parenchyma and vasculature is an invariant event in the pathogenesis of both sporadic and familial Alzheimer cases. Amyloid β-peptide originates from a larger precursor, the amyloid precursor protein (APP) ubiquitously expressed. Among the different peripheral cells expressing APP forms, platelets are particularly interesting since they show concentrations of its isoforms equivalent to those found in brain. Moreover, a number of laboratories independently described alterations in APP metabolism/concentration in platelets of Alzheimer patients when compared to control subjects matched for demographic characteristics. These observations defined the frame of our work aimed to investigate if a correlation between levels of platelet APP forms and Alzheimer disease could be detected. We have reported that patients affected by Alzheimer disease show a differential level of platelet APP forms. This observation has several implications: APP processing abnormalities, believed to be a very early change in Alzheimer disease in neuronal compartment, do occur in extraneuronal tissues, such as platelets, thus, suggesting that Alzheimer disease is a systemic disorder; further, our data strongly indicate that a differential level of platelet APP isoforms can be considered a potential peripheral marker of Alzheimer disease allowing for discrimination between Alzheimer and other types of dementia. Copyright (C) 2000 Elsevier Science B.V.

AB - Alzheimer disease is a progressive neurodegenerative disease, characterised by a progressive cognitive and memory decline. From a neuropathological point of view, Alzheimer disease is defined by the presence of characteristic lesions, i.e. mature senile plaques, neurofibrillary tangles (NFTs) and amyloid angiopathy. In particular, accumulation of the amyloid β-peptide in the brain parenchyma and vasculature is an invariant event in the pathogenesis of both sporadic and familial Alzheimer cases. Amyloid β-peptide originates from a larger precursor, the amyloid precursor protein (APP) ubiquitously expressed. Among the different peripheral cells expressing APP forms, platelets are particularly interesting since they show concentrations of its isoforms equivalent to those found in brain. Moreover, a number of laboratories independently described alterations in APP metabolism/concentration in platelets of Alzheimer patients when compared to control subjects matched for demographic characteristics. These observations defined the frame of our work aimed to investigate if a correlation between levels of platelet APP forms and Alzheimer disease could be detected. We have reported that patients affected by Alzheimer disease show a differential level of platelet APP forms. This observation has several implications: APP processing abnormalities, believed to be a very early change in Alzheimer disease in neuronal compartment, do occur in extraneuronal tissues, such as platelets, thus, suggesting that Alzheimer disease is a systemic disorder; further, our data strongly indicate that a differential level of platelet APP isoforms can be considered a potential peripheral marker of Alzheimer disease allowing for discrimination between Alzheimer and other types of dementia. Copyright (C) 2000 Elsevier Science B.V.

KW - Alzheimer disease

KW - Amyloid precursor protein (APP)

KW - Diagnosis

KW - Platelet

UR - http://www.scopus.com/inward/record.url?scp=0034730466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034730466&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(00)00559-8

DO - 10.1016/S0014-2999(00)00559-8

M3 - Article

VL - 405

SP - 277

EP - 283

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -